世界の良性前立腺肥大症薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Benign Prostate Hyperplasia Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-3895
• 出版社/出版日：QYResearch / 2021年6月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、109ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査レポートでは、良性前立腺肥大症薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（αブロッカー、5-αリダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。
・市場概要
・良性前立腺肥大症薬の市場動向
・企業の競争状況、市場シェア
・良性前立腺肥大症薬の種類別市場規模と予測2016-2027（αブロッカー、5-αリダクターゼ阻害剤、ホスホジエステラーゼ-5阻害剤、その他）
・良性前立腺肥大症薬の用途別市場規模と予測2016-2027（病院、診療所、その他）
・良性前立腺肥大症薬の北米市場規模2016-2027（アメリカ、カナダ）
・良性前立腺肥大症薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等）
・良性前立腺肥大症薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・良性前立腺肥大症薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・良性前立腺肥大症薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Sanofi、Coloplast、Pfizer、Merck、GlaxoSmithKline、Eli Lilly and Company、Abbott Laboratories、Teva Pharmaceuticals、Allergan、Boehringer Ingelheim）
・結論

The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations.

Market Analysis and Insights: Global Benign Prostate Hyperplasia Drugs Market
The global Benign Prostate Hyperplasia Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Benign Prostate Hyperplasia Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Benign Prostate Hyperplasia Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Benign Prostate Hyperplasia Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Benign Prostate Hyperplasia Drugs market.

Global Benign Prostate Hyperplasia Drugs Scope and Market Size
Benign Prostate Hyperplasia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Benign Prostate Hyperplasia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others

Segment by Application
Hospital
Clinic
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Alpha Blocker
1.2.3 5-Alpha Reductase Inhibitor
1.2.4 Phosphodiesterase-5 Inhibitor
1.2.5 Others
1.3 Market by Application
1.3.1 Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Benign Prostate Hyperplasia Drugs Market Perspective (2016-2027)
2.2 Benign Prostate Hyperplasia Drugs Growth Trends by Regions
2.2.1 Benign Prostate Hyperplasia Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Benign Prostate Hyperplasia Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Benign Prostate Hyperplasia Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Benign Prostate Hyperplasia Drugs Industry Dynamic
2.3.1 Benign Prostate Hyperplasia Drugs Market Trends
2.3.2 Benign Prostate Hyperplasia Drugs Market Drivers
2.3.3 Benign Prostate Hyperplasia Drugs Market Challenges
2.3.4 Benign Prostate Hyperplasia Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Benign Prostate Hyperplasia Drugs Players by Revenue
3.1.1 Global Top Benign Prostate Hyperplasia Drugs Players by Revenue (2016-2021)
3.1.2 Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Benign Prostate Hyperplasia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Benign Prostate Hyperplasia Drugs Revenue
3.4 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio
3.4.1 Global Benign Prostate Hyperplasia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Benign Prostate Hyperplasia Drugs Revenue in 2020
3.5 Benign Prostate Hyperplasia Drugs Key Players Head office and Area Served
3.6 Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service
3.7 Date of Enter into Benign Prostate Hyperplasia Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Benign Prostate Hyperplasia Drugs Breakdown Data by Type
4.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Type (2016-2021)
4.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2022-2027)

5 Benign Prostate Hyperplasia Drugs Breakdown Data by Application
5.1 Global Benign Prostate Hyperplasia Drugs Historic Market Size by Application (2016-2021)
5.2 Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Benign Prostate Hyperplasia Drugs Market Size (2016-2027)
6.2 North America Benign Prostate Hyperplasia Drugs Market Size by Type
6.2.1 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021)
6.2.2 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027)
6.2.3 North America Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2027)
6.3 North America Benign Prostate Hyperplasia Drugs Market Size by Application
6.3.1 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021)
6.3.2 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027)
6.3.3 North America Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2027)
6.4 North America Benign Prostate Hyperplasia Drugs Market Size by Country
6.4.1 North America Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021)
6.4.2 North America Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Benign Prostate Hyperplasia Drugs Market Size (2016-2027)
7.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Type
7.2.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021)
7.2.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027)
7.2.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2027)
7.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Application
7.3.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021)
7.3.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027)
7.3.3 Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2027)
7.4 Europe Benign Prostate Hyperplasia Drugs Market Size by Country
7.4.1 Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021)
7.4.2 Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size (2016-2027)
8.2 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Type
8.2.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Application
8.3.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Region
8.4.1 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Benign Prostate Hyperplasia Drugs Market Size (2016-2027)
9.2 Latin America Benign Prostate Hyperplasia Drugs Market Size by Type
9.2.1 Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2027)
9.3 Latin America Benign Prostate Hyperplasia Drugs Market Size by Application
9.3.1 Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2027)
9.4 Latin America Benign Prostate Hyperplasia Drugs Market Size by Country
9.4.1 Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size (2016-2027)
10.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Type
10.2.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application
10.3.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Country
10.4.1 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Details
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Benign Prostate Hyperplasia Drugs Introduction
11.1.4 Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.1.5 Sanofi Recent Development
11.2 Coloplast
11.2.1 Coloplast Company Details
11.2.2 Coloplast Business Overview
11.2.3 Coloplast Benign Prostate Hyperplasia Drugs Introduction
11.2.4 Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.2.5 Coloplast Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Benign Prostate Hyperplasia Drugs Introduction
11.3.4 Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Benign Prostate Hyperplasia Drugs Introduction
11.4.4 Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.4.5 Merck Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Benign Prostate Hyperplasia Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.5.5 GlaxoSmithKline Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Details
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Benign Prostate Hyperplasia Drugs Introduction
11.6.4 Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.6.5 Eli Lilly and Company Recent Development
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Company Details
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Benign Prostate Hyperplasia Drugs Introduction
11.7.4 Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.7.5 Abbott Laboratories Recent Development
11.8 Teva Pharmaceuticals
11.8.1 Teva Pharmaceuticals Company Details
11.8.2 Teva Pharmaceuticals Business Overview
11.8.3 Teva Pharmaceuticals Benign Prostate Hyperplasia Drugs Introduction
11.8.4 Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.8.5 Teva Pharmaceuticals Recent Development
11.9 Allergan
11.9.1 Allergan Company Details
11.9.2 Allergan Business Overview
11.9.3 Allergan Benign Prostate Hyperplasia Drugs Introduction
11.9.4 Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.9.5 Allergan Recent Development
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Details
11.10.2 Boehringer Ingelheim Business Overview
11.10.3 Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Introduction
11.10.4 Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021)
11.10.5 Boehringer Ingelheim Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Benign Prostate Hyperplasia Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Alpha Blocker
Table 3. Key Players of 5-Alpha Reductase Inhibitor
Table 4. Key Players of Phosphodiesterase-5 Inhibitor
Table 5. Key Players of Others
Table 6. Global Benign Prostate Hyperplasia Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Benign Prostate Hyperplasia Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Benign Prostate Hyperplasia Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2016-2021)
Table 10. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2022-2027)
Table 12. Benign Prostate Hyperplasia Drugs Market Trends
Table 13. Benign Prostate Hyperplasia Drugs Market Drivers
Table 14. Benign Prostate Hyperplasia Drugs Market Challenges
Table 15. Benign Prostate Hyperplasia Drugs Market Restraints
Table 16. Global Benign Prostate Hyperplasia Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Benign Prostate Hyperplasia Drugs Market Share by Players (2016-2021)
Table 18. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2020)
Table 19. Ranking of Global Top Benign Prostate Hyperplasia Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Benign Prostate Hyperplasia Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Benign Prostate Hyperplasia Drugs Product Solution and Service
Table 23. Date of Enter into Benign Prostate Hyperplasia Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Benign Prostate Hyperplasia Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Benign Prostate Hyperplasia Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. Sanofi Company Details
Table 64. Sanofi Business Overview
Table 65. Sanofi Benign Prostate Hyperplasia Drugs Product
Table 66. Sanofi Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 67. Sanofi Recent Development
Table 68. Coloplast Company Details
Table 69. Coloplast Business Overview
Table 70. Coloplast Benign Prostate Hyperplasia Drugs Product
Table 71. Coloplast Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 72. Coloplast Recent Development
Table 73. Pfizer Company Details
Table 74. Pfizer Business Overview
Table 75. Pfizer Benign Prostate Hyperplasia Drugs Product
Table 76. Pfizer Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 77. Pfizer Recent Development
Table 78. Merck Company Details
Table 79. Merck Business Overview
Table 80. Merck Benign Prostate Hyperplasia Drugs Product
Table 81. Merck Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 82. Merck Recent Development
Table 83. GlaxoSmithKline Company Details
Table 84. GlaxoSmithKline Business Overview
Table 85. GlaxoSmithKline Benign Prostate Hyperplasia Drugs Product
Table 86. GlaxoSmithKline Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 87. GlaxoSmithKline Recent Development
Table 88. Eli Lilly and Company Company Details
Table 89. Eli Lilly and Company Business Overview
Table 90. Eli Lilly and Company Benign Prostate Hyperplasia Drugs Product
Table 91. Eli Lilly and Company Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 92. Eli Lilly and Company Recent Development
Table 93. Abbott Laboratories Company Details
Table 94. Abbott Laboratories Business Overview
Table 95. Abbott Laboratories Benign Prostate Hyperplasia Drugs Product
Table 96. Abbott Laboratories Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 97. Abbott Laboratories Recent Development
Table 98. Teva Pharmaceuticals Company Details
Table 99. Teva Pharmaceuticals Business Overview
Table 100. Teva Pharmaceuticals Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 101. Teva Pharmaceuticals Recent Development
Table 102. Allergan Company Details
Table 103. Allergan Business Overview
Table 104. Allergan Benign Prostate Hyperplasia Drugs Product
Table 105. Allergan Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 106. Allergan Recent Development
Table 107. Boehringer Ingelheim Company Details
Table 108. Boehringer Ingelheim Business Overview
Table 109. Boehringer Ingelheim Benign Prostate Hyperplasia Drugs Product
Table 110. Boehringer Ingelheim Revenue in Benign Prostate Hyperplasia Drugs Business (2016-2021) & (US$ Million)
Table 111. Boehringer Ingelheim Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Benign Prostate Hyperplasia Drugs Market Share by Type: 2020 VS 2027
Figure 2. Alpha Blocker Features
Figure 3. 5-Alpha Reductase Inhibitor Features
Figure 4. Phosphodiesterase-5 Inhibitor Features
Figure 5. Others Features
Figure 6. Global Benign Prostate Hyperplasia Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Other Case Studies
Figure 10. Benign Prostate Hyperplasia Drugs Report Years Considered
Figure 11. Global Benign Prostate Hyperplasia Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Benign Prostate Hyperplasia Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Benign Prostate Hyperplasia Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Benign Prostate Hyperplasia Drugs Market Share by Regions (2022-2027)
Figure 15. Global Benign Prostate Hyperplasia Drugs Market Share by Players in 2020
Figure 16. Global Top Benign Prostate Hyperplasia Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostate Hyperplasia Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Benign Prostate Hyperplasia Drugs Revenue in 2020
Figure 18. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Benign Prostate Hyperplasia Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Benign Prostate Hyperplasia Drugs Market Share by Type (2016-2027)
Figure 22. North America Benign Prostate Hyperplasia Drugs Market Share by Application (2016-2027)
Figure 23. North America Benign Prostate Hyperplasia Drugs Market Share by Country (2016-2027)
Figure 24. United States Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Benign Prostate Hyperplasia Drugs Market Share by Type (2016-2027)
Figure 28. Europe Benign Prostate Hyperplasia Drugs Market Share by Application (2016-2027)
Figure 29. Europe Benign Prostate Hyperplasia Drugs Market Share by Country (2016-2027)
Figure 30. Germany Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Benign Prostate Hyperplasia Drugs Market Share by Region (2016-2027)
Figure 40. China Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Benign Prostate Hyperplasia Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Benign Prostate Hyperplasia Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Benign Prostate Hyperplasia Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Benign Prostate Hyperplasia Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Benign Prostate Hyperplasia Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Sanofi Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 60. Coloplast Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 61. Pfizer Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 62. Merck Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 63. GlaxoSmithKline Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 64. Eli Lilly and Company Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 65. Abbott Laboratories Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 66. Teva Pharmaceuticals Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 67. Allergan Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 68. Boehringer Ingelheim Revenue Growth Rate in Benign Prostate Hyperplasia Drugs Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

以下、関連資料のご紹介

世界の良性前立腺肥大症治療市場規模・現状・予測（2021年-2027年）

Global Benign Prostatic Hyperplasia Treatment Market Size, Status and Forecast 2021-2027
QFJ1-5097 2021年6月 121Pages
QYResearch社発行の本調査レポートでは、良性前立腺肥大症治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（医薬品用、低侵襲手術用、レーザー治療用、その他）、用途別市場規模（病院、外来手術センター、専門クリニック、その他）、主要地域別市場規...

世界の良性前立腺肥大症治療装置市場規模・現状・予測（2021年-2027年）

Global Benign Prostatic Hyperplasia Treatment Equipments Market Size, Status and Forecast 2021-2027
QFJ1-5098 2021年6月 128Pages
QYResearch社発行の本調査レポートでは、良性前立腺肥大症治療装置の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（外科治療機器、低侵襲治療機器、レーザー治療機器、その他）、用途別市場規模（病院＆診療所、外来手術センター（ASC）、家庭用、その...

世界の前立腺がん市場規模・現状・予測（2021年-2027年）

Global Prostate Cancer Market Size, Status and Forecast 2021-2027
QFJ1-4769 2021年6月 96Pages
QYResearch社発行の本調査レポートでは、前立腺がんの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ホルモン感受性前立腺がん、ホルモン不応性前立腺がん）、用途別市場規模（化学療法、ホルモン療法、標的療法、免疫療法）、主要地域別市場規模（北米、...

世界の前立腺がん治療市場規模・現状・予測（2021年-2027年）

Global Prostate Cancer Medicine Market Size, Status and Forecast 2021-2027
QFJ1-4770 2021年6月 106Pages
QYResearch社発行の本調査レポートでは、前立腺がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（LHRH拮抗薬、LHRHアナログ、抗アンドロゲン、ホルモン療法用パイプライン薬）、用途別市場規模（病院、その他）、主要地域別市場規模（北米...

良性前立腺過形成の治療のグローバル市場：規模・現状・予測2019-2025

Global Benign Prostatic Hyperplasia Treatment Market Size, Status and Forecast 2019-2025
QYR9NV17685 2019年11月18日 130Pages
※当調査レポートでは、良性前立腺過形成の治療の世界市場について調査・分析し、良性前立腺過形成の治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（薬物クラス、低侵襲手術、レーザー治療、その他）、用途...

良性前立腺過形成の治療のグローバル市場：規模・現状・予測2019-2025

世界の去勢抵抗性前立腺がん治療市場規模・現状・予測（2021年-2027年）

Global Castrate-resistant Prostate Cancer Treatment Market Size, Status and Forecast 2021-2027
QFJ1-3976 2021年6月 99Pages
QYResearch社発行の本調査レポートでは、去勢抵抗性前立腺がん治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、ホルモン療法、免疫療法、放射線療法）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州...

世界の前立腺がん分子診断市場規模・現状・予測（2021年-2027年）

Global Prostate Cancer Molecular Diagnostics Market Size, Status and Forecast 2021-2027
QFJ1-4771 2021年6月 109Pages
QYResearch社発行の本調査レポートでは、前立腺がん分子診断の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（PCR、FISH、DNAシーケンシング、ジーンチップ）、用途別市場規模（臨床診断、薬物スクリーニング、研究）、主要地域別市場規模（北米...

世界の去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬市場規模・現状・予測（2021年-2027年）

Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size, Status and Forecast 2021-2027
QFJ1-3977 2021年6月 97Pages
QYResearch社発行の本調査レポートでは、去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（経口療法、注射療法）、用途別市場規模（病院＆診療所、家庭用、外来手術センター（ASC））、主要地域別...

世界の前立腺特異抗原（PSA）バイオマーカー市場規模・現状・予測（2021年-2027年）

Global Prostate Specific Antigen (PSA) Biomarker Market Size, Status and Forecast 2021-2027
QFJ1-4772 2021年6月 106Pages
QYResearch社発行の本調査レポートでは、前立腺特異抗原（PSA）バイオマーカーの世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（血、精液、尿）、用途別市場規模（診断、創薬、個別化医療、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア...

世界の良性前立腺肥大症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Benign Prostatic Hyperplasia Treatment Market The global Benign Prostatic Hyperplasia Treatment market size is projected to reach US$ 8438.6 million by 2027, from US$ 6476.6 million in 2020, at a CAGR of 3.4% during 2021-2027. With industry-standard accuracy in a…
世界の良性前立腺肥大症治療装置市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Benign Prostatic Hyperplasia Treatment Equipments Market The global Benign Prostatic Hyperplasia Treatment Equipments market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard …
良性前立腺過形成の治療のグローバル市場：規模・現状・予測2019-2025 In 2018, the global Benign Prostatic Hyperplasia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Benign Prostatic Hyperplasia Treatment status, future forecast, growth oppor…
良性前立腺過形成の治療のグローバル市場：規模・現状・予測2019-2025 In 2018, the global Benign Prostatic Hyperplasia Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Benign Prostatic Hyperplasia Treatment status, future forecast, growth oppor…
世界のVEGF阻害薬市場規模・現状・予測（2021年-2027年） Vascular endothelial growth factor (VEGF) is an angiogenic factor responsible for the formation of blood vessels either from already existing blood vessels or from vascular endothelial cells. Market Analysis and Insights: Global VEGF Inhibitor Drugs Market The global VEGF Inhibitor Drugs market size…